行情

GLPG

GLPG

Galapagos
NASDAQ

实时行情|Nasdaq Last Sale

260.04
-6.64
-2.49%
盘后: 260.00 -0.04 -0.02% 16:49 02/20 EST
开盘
266.80
昨收
266.68
最高
267.50
最低
257.23
成交量
26.44万
成交额
--
52周最高
270.15
52周最低
94.75
市值
161.10亿
市盈率(TTM)
53.99
分时
5日
1月
3月
1年
5年

分析师评级

11位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

GLPG 新闻

  • Sell-siders cut views on Tivity Health after ugly Q4
  • Seeking Alpha - Article.11小时前
  • The Daily Biotech Pulse: Heron Pain Drug Review Extended, Disappointment For Teva In Tourette Syndrome Study
  • Benzinga.12小时前
  • RBC Capital Downgrades Galapagos to Underperform, Announces $175 Price Target
  • Benzinga.12小时前
  • Where Will Gilead Sciences Be in 10 Years?
  • MotleyFool.com.1天前

更多

所属板块

生物技术和医学研究
+0.09%
制药与医学研究
-0.40%

热门股票

名称
价格
涨跌幅

GLPG 简况

Galapagos NV is a Belgium-based clinical-stage biotechnology company. The Company is focused on the discovery and development of small molecule medicines with novel modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The Company aims to develop a portfolio of clinical-stage therapies for the enhancement of existing treatment paradigms. In addition, the Company’s mission is to develop a number of medicines based on the discovery of novel targets. Galapagos NV also discovers which proteins that are involved in causing diseases such as, rheumatoid, arthritis, inflammatory bowel disease and fibrosis. Galapagos aims to develop small molecules that inhibit these targets, restore the balance and thereby positively influence the course of the disease.
展开

Webull提供Galapagos NV的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。